FMT and Other Gut Microbial Therapies National Registry
The AGA FMT and Other Gut Microbial Therapies National Registry will assess short- and long-term patient outcomes associated with FMT and other microbial therapies. This registry is a program of the AGA Institute and AGA Center for Gut Microbiome Research & Education.
If you perform fecal microbiota transplantation (FMT), we encourage you to participate in this national data collection project. Our goal is to track 2,200 patients for 10 years. The data we collect will allow us to identify potential short-term adverse outcomes and to search for long-term safety concerns, such as development of chronic conditions like irritable bowel syndrome, obesity and diabetes. Please contribute to advancing the future of FMT — the information available to you and your patients at the end of this initiative will be worth it.
News about the AGA FMT and Other Gut Microbial Therapies National Registry
With this milestone, the FMT registry is officially halfway to the goal of tracking 2,200 patients. Thank you to the 37 clinical sites across the U.S. who have contributed to this success.
On Nov. 30, 2022, FDA approved the first fecal microbiota therapy for recurrent CDI, Rebyota®. FDA also issued new requirements for stool banks and health care professionals using FMT material.
Published in Gastroenterology, the registry reported that FMT led to a cure of C. difficile infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.
With this milestone, the FMT registry is officially underway. The AGA FMT National Registry also announces collaborations with American Gut and OpenBiome.
In this article Genome Magazine profiles AGA’s Fecal Microbiota Transplantation National Registry, which will be the largest data set of long-term outcomes for this procedure.
In this Gastroenterology commentary, the registry co-principal investigators discuss the impetus and goals for this massive data collection initiative.
Read our initial announcement of the AGA FMT National Registry.
Patient information on the AGA FMT and Other Gut Microbial Therapies National Registry
Visit Clinicaltrials.gov to see the sites participating in this registry. You or your doctor can contact the participating sites to learn more about enrolling.
Visit this page for frequently asked questions and other information relevant to patients who have already received a FMT.
This information will help you understand if fecal microbiota transplantation is right for you.
Watch this brief video to hear as leading experts in the field explain what are fecal transplants and how they’ve changed the treatment of recurring C. difficile infection.
More on the AGA FMT and Other Gut Microbial Therapies National Registry
Hear from Loren Laine, MD, AGAF, Colleen Kelly, MD, and Gary Wu, MD, co-principal investigators for AGA’s NIH-funded FMT registry, as they explain how this registry will influence future practice and research of FMT.
Meet our funder
This project is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R24AI118629.
The content on this website is solely the responsibility of the American Gastroenterological Association and does not necessarily represent the official views of the National Institutes of Health.
Meet our partner societies
Meet our registry collaborators
Meet our steering committee
The FMT Registry Steering Committee oversees registry operations, ensures compliance with clinical protocol and applicable regulations, and provides general direction for the registry.
Colleen Kelly, MD
Co-Chair and Prinicipal Investigator,
Brown University Women's Medicine and Collaborative
Loren Laine, MD, AGAF
Co-Chair and Co-Principal Investigator,
Yale School of Medicine
Gary Wu, MD
Co-Principal Investigator,
University of Pennsylvania
Ashish Atreja, MD, MPH
Health Information Technology Expert,
UC Davis Health
Stacy Kahn, MD
NASPGHAN Liaison,
Boston Children’s Hospital
James Lewis, MD, MSCE, AGAF
Clinical Epidemiology Expert,
University of Pennsylvania
Brendan J. Kelly, MD, MS
IDSA Liaison,
University of Pennsylvania
Andres Hurtado-Lorenzo, PhD
CCF Liaison,
Crohn's & Colitis Foundation
Alexander Khoruts, MD
FMT and Microbiota-Based Therapeutics Expert,
University of Minnesota
Gail Hecht, MD
Clinical Microbiology Expert,
Loyola University Medical Center
Rob Knight, PhD
Microbiome Analytics Expert,
University of California, San Diego
Brought to you by the
